David Sibon

18PUBLICATIONS
84CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 04, 2025
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant

|Mar 03, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Vincent Camus, Thierry Molina, Fabienne Desmots

|Sep 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).

Olivier Tournilhac, Bettina Altmann, Birte Friedrichs

|Jun 12, 2024
Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.

Layla Veleanu, Laurence Lamant, David Sibon

|May 16, 2023
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

A Marouf, N Molinari, D Sibon

|Apr 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Guillaume Cartron, Emmanuel Bachy, Hervé Tilly

Pageof 3

Frequent Collaborators

6 joint publications

Gandhi Laurent Damaj

6 joint publications

Franck Morschhauser

5 joint publications

Olivier Tournilhac

5 joint publications

Roch Houot